Life Span of Cells Extended by ANTICORT
Steroidogenesis' - STGI - ANTICORT To Be Used To Treat A Disease of Aging
LAS VEGAS--(BUSINESS WIRE)--May 18, 1999--Steroidogenesis Inhibitors International (OTCBB:STGI, Berlin Exch.:SSJ) today announced that it has been notified by the Institute of Oncology in Bucharest, Romania, that ANTICORT(TM) has already increased the life span of cultured fibroblast cells by 75%.
Earlier this year, STGI has provided the Institute with a sample of ANTICORT to be used in a research program dealing with attempts to extend the life span of cells grown in tissue cultures and to ascertain new approaches to the treatment of cancerous cells in an effort to find new leads of treating aging and cancer.
New research on aging is exploding with new information about causes and treatments. In a paper published late last week, scientists from Columbia University in New York reported finding an enzyme in worms, which makes them live longer. This discovery, the authors of the paper state, raises the hopes of finding treatments of Alzheimer's and other diseases associated with aging.
In this context, there is renewed interest in the concept of high cortisol playing a major role in aging and Alzheimer's and the potential role of anticortisols. Papers by top scientists from Rockefeller University, Salk Institute, Stanford University and Bowman-Gray School of Medicine, Wake Forest University in Winston-Salem, NC, show strong evidence about the destructive role of cortisol on the hippocampus, the memory center of the brain, with a top scientist from the Endocrine Section, Gerontology Research Center, Baltimore, MD, stating "Cortisol levels go up with age...If it were to become possible to block the rise in cortisol, or to lower elevated cortisol levels in the elderly, it should have a very important impact on aging."
Fully aware of the connection between cortisol and aging, STGI has assembled all the documentation necessary to submit an application (in the US and/or abroad), to proceed with a clinical study in which its anticortisol drug ANTICORT will be used to treat a certain condition which significantly increases the risk of death among elderly men and women.
This release may include "forward-looking statement" within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1034. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable it can give no assurance that such expectations will prove correct. This is neither an offer to buy or sell a security. For informational purposes only, from sources deemed to be reliable. For more information visit our World Wide Web page at www.anticort.com.
CONTACT: Steroidogenesis, Las Vegas
Janet Greeson, Ph.D
702/735-7001
or
H.L. Lanzet Inc.
Herbert Lanzet
DeeDee Lanzet
212/687-0061
or
Performance Strategies
Richard L. Brown
Chuck Jordan
303/948-3601
|
